BioControl Becomes Latest Company To Report Disappointing Outcomes With VNS Therapy For Heart Failure
This article was originally published in Clinica
BioControl Medical has terminated the INOVATE HF trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure, after a pre-specified interim analysis showed the trial had little chance of meeting its primary endpoint.
You may also be interested in...
The physician who led the first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.